Qu Biologics is a biotechnology company developing site specific immunomodulators that aim to restore normal immune function in the targeted diseased organ. Its IBD advisory team provides guidance and oversight of Qu Biologic’s IBD studies.
Dr. Panaccione is director of the Inflammatory Bowel Disease Clinic and Gastroenterology Training Program at the University of Calgary in Canada.
More articles on Gastroenterology:
Dr. Christopher Radawski joins Bronson Gastroenterology Portage
Polson Health plans new GI clinic in Montana
GI View FDA clearance, $129k Boston Scientific stock transaction & more – 5 recent GI/endoscopy key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.